Connect Biopharma Holdings Ltd

CNTBNASDAQ · USD
0.61USD-0.07 (-10.39%)
132

Connect Biopharma Holdings Ltd (CNTB) Implied Volatility Current

CNTB's 30 day implied volatility is 8,361.29%, with an IV Rank of 94.84%. This is a high IV Rank versus the past year, meaning Connect Biopharma Holdings Ltd options are relatively expensive and currently favor sellers. CNTB's 30 day historical volatility sits at 64.45%, which means implied volatility is running 8,296.84 points above historical volatility, as of Nov 13, 2026.

Read more

Tracking CNTB implied volatility helps you spot when Connect Biopharma Holdings Ltd options are historically cheap or expensive, and where the best trades are hiding. When CNTB IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CNTB implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CNTB IV rank helps you see whether CNTB's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation.

Implied Volatility

IV Rank
94.84%IV Rank
High

IV is highly elevated. Premiums are expensive, strongly favoring sellers.

Implied Volatility (30d)8361.29%

IV Rank94.84%

Historical Volatility (30d)64.45%

IV Minus HV+8,296.84%

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →